Main menu
  1. Home
  2.  » 
  3. Catalent News
  4.  » Catalent Expands Nasal Drug Development and Manufacturing Capabilities at Morrisville, North Carolina, Facility

Catalent Expands Nasal Drug Development and Manufacturing Capabilities at Morrisville, North Carolina, Facility

SOMERSET, N.J. – April 28, 2022 — Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, Research Triangle Park (RTP), North Carolina, facility, to provide world-class services for the development and manufacturing of unit and bi-dose nasal spray products. This marks the first phase of a multi-million-dollar investment at the site to expand and modernize its nasal drug delivery capabilities, substantially increasing technology and capacity to support projected growth for existing and future customers. The expansion is in response to the growing interest in the potential for nose-to-brain drug administration, and as an alternative route for the delivery of systemic drugs, rescue therapies, and vaccines.

Catalent’s RTP site has supported numerous nasal programs from early formulation, clinical, and commercial production, and the newly completed first phase investment will provide a flexible, high speed micro vial filling line, automated inspection, and high-speed assembly line capable of supporting unit and bi-dose programs. The additional technologies are intended to allow seamless transition for all clinical and commercial manufacturing within an ISO 7 environment and spray testing development and release.

“Our team in Morrisville has a long history of success in developing and commercializing nasal drug products, and we are witnessing a growth in this field from innovators looking to exploit its advantage, such as its fast onset of action and being non-invasive,” said Jonathan Arnold, President of Oral and Specialty Delivery at Catalent. “This initial investment at the site has allowed us to integrate expertise across a range of disciplines, including analytical sciences, formulation development and manufacturing, with the latest in product filling technology, enabling researchers to accelerate nasal drug product programs, and commercialize new medicines as fast as possible.”

Catalent’s 186,000-square-foot facility in Morrisville is located within the Research Triangle Park, and is the company’s center of excellence for nasal drug development, as well as providing services for analytical services, biologics, supporting small and large molecule projects.

ABOUT CATALENT

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of nearly 7,000 products annually. Catalent’s expert workforce exceeds 19,000, including more than 2,500 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com

 

More products. Better treatments. Reliably supplied.™